A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant

This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell transplant (haploHCT) for the treatment of patients with severe aplastic anemia that does not respond to treatment (refractory) or that has come back (recurrent). Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid. It may also lower the body's immune response. Pentostatin blocks a protein needed for cell growth. Anti-thymocyte globulin is an immunosuppressive drug can destroy immune cells known as T-cells. HaploHCT transfers blood-forming stem cells from a healthy partially-matched donor to a patient. Administering a regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin before haploHCT may help make room for the new, healthy cells and may reduce the risk of graft versus host disease.

Start Date15 Nov 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

ChiCTR2300075075

/ RecruitingPhase 2IIT

A Phase IIA Clinical Study of Toripalimab Combined with DCF Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Start Date01 Sep 2023

Sponsor / Collaborator

Fujian Provincial Hospital

JPRN-UMIN000047881

/ RecruitingPhase 2IIT

Feasibility Study of Preoperative DCF Therapy in Esophageal Cancer - FEVER trial

Start Date03 Oct 2022

Sponsor / Collaborator

Kobe University

100 Clinical Results associated with Pentostatin

100 Translational Medicine associated with Pentostatin

100 Patents (Medical) associated with Pentostatin

2,371

Literatures (Medical) associated with Pentostatin

01 Mar 2026·ENVIRONMENTAL RESEARCH

Multi-active sites of Co/N-biochar created by ball-milling for peroxymonosulfate-activated degradation of diclofenac

Article

Author: Zheng, Meng-Wei ; Yang, Hui-Min ; Chou, Pei-Hsin ; Liu, Shou-Heng

A cobalt-nitrogen co-doped biochar catalyst (Co/N-BC-300) was synthesized from spent coffee grounds via urea-assisted ball milling and low-temperature pyrolysis for peroxymonosulfate (PMS) activation in diclofenac (DCF) degradation. Ball milling successfully disperses cobalt precursors, increases surface defects, and enhances nitrogen doping. These structural improvements expose active sites, thereby accelerating PMS activation and electron transfer. The optimized catalyst achieves complete DCF removal within 7 min under mild conditions. Quenching and electron paramagnetic resonance analyses confirm singlet oxygen (¹O₂) was the dominant species in a non-radical degradation pathway with superoxide radicals (O₂^•-) serving as secondary contributors. Furthermore, density functional theory calculations are used to identify key electrophilic and radical attack sites, supporting the proposed mechanisms. The catalyst demonstrates excellent stability, maintaining >93 % activity after five regeneration cycles with negligible cobalt leaching. Also, the catalytic performance can be maintained in natural water matrices containing organic matter and coexisting anions. Toxicity assessments confirm that the degradation intermediates pose a low environmental risk. This study highlights the dual benefits of waste valorization and ball milling-assisted catalyst engineering in advancing PMS-based water treatment technologies.

01 Feb 2026·TALANTA

An electrochemical diclofenac sensor based on an electrode modified with nitrogen-doped biomass-derived carbon and molybdenum trioxide nanoparticles

Article

Author: Kongkeaw, Supatinee ; Limbut, Warakorn ; Phonchai, Apichai ; Cotchim, Suparat ; Torrarit, Kamonchanok ; Thipwimonmas, Yudtapum

Diclofenac (DCF) is a widely used non-steroidal anti-inflammatory drug (NSAID). However, its extensive use has raised health concerns, as overdoses can lead to serious adverse effects. In this research, we developed a novel and portable electrochemical sensor for DCF, which is capable of providing real-time analysis. To promote environmental sustainability, carbon derived from biomass was utilized. Cow dung (CD), a globally abundant and renewable biomass, was selected as the carbon precursor due to its excellent characteristics, including high porosity and large surface area, which are highly beneficial for electrode modification. To enhance electrochemical performance, CD was doped with nitrogen (CD-N) and functionalized with molybdenum trioxide nanoparticles (MoO₃NPs). This composite structure significantly improves the electrochemical properties by providing enhanced stability, increased active sites, a larger electroactive surface area, and superior electron mobility, making it a highly effective material for DCF detection. The modified electrode showed an increased active surface area and an improvement in electron transfer performance for DCF oxidation. Under optimal conditions, the electrochemical oxidation of DCF was excellent with a linear range of 0.25-50.00 μmol L^-1. The limit of detection was 0.08 μmol L^-1. The developed sensor was successfully applied to determine DCF in artificial urine samples, and the results were in accordance with those of spectrophotometric analysis.

01 Feb 2026·WATER RESEARCH

UVB-activated permanganate enables rapid emerging organic contaminants decontamination through synergistic HO• and reactive manganese species

Article

Author: Su, Peng ; Hou, Xiangyang ; Yang, Tao ; Lv, Qixiao ; Lu, Qiuling ; Li, Ping ; Xu, Jucai ; Xu, Ying ; Ma, Jun

Permanganate [Mn(VII)] has been widely used as oxidants in water treatment. However, the limited reactivity of Mn(VII) with some recalcitrant contaminants impeded its application. In this study, UVB was introduced for Mn(VII) activation, and 95.1% of diclofenac (DCF) and 92.7% of p-hydroxybenzoic acid (p-HBA) were degraded by UVB/Mn(VII) after 30 min treatment while Mn(VII) alone were 36.6% and 25.2%, respectively. Hydroxyl radical (HO•) and reactive manganese species (RMnS) were main reactive species in UVB/Mn(VII) process. The contributions of HO• and RMnS (hypomanganate [Mn(V)] and trivalent manganese [Mn(III)]) to DCF degradation were respectively 25.2% and 55.0%, while those to p-HBA were 19.7% and 67.2% at 310 nm irradiation with 200 μM Mn(VII) and pH 7.0. The dominant RMnS responsible for DCF degradation was Mn(V) while that for p-HBA was Mn(III). When the UV wavelength increased from 255 nm to 310 nm, k_obs of DCF and p-HBA decreased from 0.1510 min^-1 to 0.1005 min^-1 and from 0.1395 min^-1 to 0.0869 min^-1, respectively, with the quantum yields of Mn(VII) decreased from 0.200 mol/E to 0.014 mol/E. Comparatively, k_obs of DCF and p-HBA increased as Mn(VII) dosage increased from 50 μM to 400 μM. When the pH increased from 5.0 to 9.0, the degradation efficiencies of DCF and p-HBA decreased, which was due to the lower oxidation capacity and quantum yields of Mn(VII) in alkaline conditions. The contributions of HO• decreased with the increase of pH, while those of RMnS increased and played the dominant role. As RMnS were resistant to the interference of anions, Cl^- and HCO₃^- had negligible influences on DCF and p-HBA degradation. HA as RMnS stabilizing substance enhanced the degradation of DCF and p-HBA. The removal efficiencies of DCF and p-HBA in real water backgrounds were >95% after 30 min treatment. The high adaptability of UVB/Mn(VII) in complicated environments indicated its application potential in water treatment.

News (Medical) associated with Pentostatin

28 Jan 2026

·www.businesswire.com

Shorla Oncology® Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, in a larger vial size, 375mg/75mL, for adult and pediatric patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). Nelarabine Injection carries a Boxed Warning. Please see Important Safety Information below and full Prescribing Information, including a Boxed Warning. This larger vial size is the second FDA approval of Nelarabine Injection from Shorla, both using the same formulation. The first approval, for a 250mg/50mL vial, was introduced to help address ongoing product shortages in the U.S. market. Depending on the dose, the new 375mg/75mL vial offers greater dosing flexibility for pediatric patients and provides higher-dosing options for adults. Its larger volume can allow for more precise dosing based on individual treatment needs. “We are delighted to offer this new larger vial size of Nelarabine Injection to better serve adult and pediatric patients with T-cell leukemia and lymphoma,” said Sharon Cunningham, CEO and Co-Founder of Shorla Oncology. “Both adult and pediatric patients have differing dose needs, which can make treatment preparation complex. With this FDA approval, we hope to support healthcare providers in delivering care more efficiently, reducing waste, and improving precision in managing these types of aggressive blood cancers.” T-cell acute lymphoblastic leukemia is an aggressive blood cancer in which too many T-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood. T-ALL affects both pediatric and adult populations, yet treatment needs differ due to variation in body surface (BSA). The median age of diagnosis for pediatric T-ALL is nine years, with an average BSA of 1.07 m², which requires a 696 mg dose. The new 375mg vial’s flexibility could enable precise dosing with fewer vials. Additionally, adult patients have an average BSA of 1.7 m² and typically demand a higher nelarabine dose of approximately 2,550 mg. “Launching Nelarabine Injection, as our first product in the U.S., was a major milestone. Expanding that footprint with a 375mg vial of Nelarabine Injection reflects our ongoing commitment to solving real-world challenges for patients with T-cell leukemia by prioritizing improvements in healthcare delivery, pharmacy workflow, and waste reduction,” said Orlaith Ryan, CTO and Co-Founder of Shorla Oncology. “This additional vial size strengthens our ability to support both clinicians and patients living with T-ALL and T-LBL, where flexibility and accuracy in dosing is important.” About Shorla Oncology Shorla Oncology is a privately held, U.S. and Ireland- based commercial-stage specialty pharmaceutical company established by Sharon Cunningham and Orlaith Ryan. The company has an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. Shorla is focused on indications where existing treatments are limited, in short supply, or the drug applications are inadequate for the target population. The company’s growing portfolio brings accessible, affordable, and life-saving treatments to patients, delivering a major contribution to patient care. Shorla currently markets four products: Nelarabine for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens, JYLAMVOTM for the treatment of acute lymphoblastic leukemia and other indications, IMKELDI for the treatment of Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors (GISTs), and other indications, and TEPULYTE® for the treatment of breast and ovarian cancer. For further information, please visit www.shorlaoncology.com. Nelarabine Injection INDICATION Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. IMPORTANT SAFETY INFORMATION WARNING: NEUROLOGIC ADVERSE REACTIONS CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Neurologic Adverse Reactions: Severe neurologic reactions have been reported. Monitor for signs and symptoms of neurologic toxicity. Hematologic Reactions: Complete blood counts including platelets should be monitored regularly. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception; and advise males to use condoms. Effects on Ability to Drive and Use Machines: Somnolence may occur. Advise patients to refrain from these activities until somnolence has resolved. ADVERSE REACTIONS The most common (≥ 20%) adverse reactions were: Adult: anemia, thrombocytopenia, neutropenia, nausea, diarrhea, vomiting, constipation, fatigue, pyrexia, cough, and dyspnea. Pediatric: anemia, neutropenia, thrombocytopenia, and leukopenia. The most common (> 10%) neurological adverse reactions were: Adult: somnolence, dizziness, peripheral neurologic disorders, hypoesthesia, headache, and paresthesia. Pediatric : headache and peripheral neurologic disorders. To report SUSPECTED ADVERSE REACTIONS, contact Shorla Oncology at 1-844-668-3940 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Administration in combination with adenosine deaminase (ADA) inhibitors, such as pentostatin, is not recommended. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. Renal Impairment: Closely monitor patients with moderate or severe renal impairment for toxicities. Hepatic Impairment: Closely monitor patients with severe hepatic impairment for toxicities. Please click here for full Prescribing Information, including Boxed Warning. All trademarks are the property of Shorla Oncology. ©SHORLA ONCOLOGY® 2026.

Drug ApprovalImmunotherapy

05 Mar 2024

·pmlive.com

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Sanofi’s Rezurock (belumosudil) will be fast-tracked by the NHS as a treatment for cancer patients living with chronic graft versus host disease (cGVHD). For the next three years, provided by funding from the Innovation Medicines Fund, around 200 patients are set to benefit from Rezurock. Affecting around a third of patients who have undergone stem cell or bone marrow transplants for blood cancers including leukaemia and lymphoma, cGVHD is a serious complication that occurs when white blood cells in donated tissue begin to attack recipients’ organs, weakening their immune system. In England, around 400 of 1,200 patients who have undergone a stem cell or bone marrow transplant will develop the disease each year, making patients more vulnerable to infections, 50% of whom will not respond to currently available treatments including pentostatin, rituximab and imatinib. Following guidance from the National Institute of Health and Care Excellence (NICE) in December last year, patients living with the most severe cases of the disease aged 12 years and older who have not had success with two prior therapies are set to benefit from Rezurock. NICE’s decision was based on results from the phase 2 ROCKstar trial, which showed that 75% of 132 patients with cGVHD aged 12 years or older receiving Rezurock achieved a response in all organs within a year of treatment. Additionally, seven patients in the modified intent-to-treat population showed a complete response in all affected organs. Taken as a tablet once a day, Rezurock works to inhibit the proteins responsible for the inflammatory response caused by cGVHD. James Palmer, medical director for specialised services, NHS England, commented: “This rollout… will help people living with this debilitating condition [to] effectively manage their symptoms and enhance their quality of life and daily functioning.” In 2019, the therapy was granted orphan drug designation by the Medicines and Healthcare products Regulatory Agency and the European Commission to treat cGVHD. More recently, Rezurock was approved by the US Food and Drug Administration in 2021 for the treatment of adults and paediatric patients aged 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy.

Clinical ResultDrug ApprovalOrphan DrugPhase 2Immunotherapy

29 Feb 2024

·www.pharmaceutical-technology.com

NHS expedites availability of Belumosudil for chronic GVHD

The once-daily tablet hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Credit: fizkes / Shutterstock.com. The National Health Service (NHS) in the UK has expedited the availability of the new drug, Belumosudil (Rezurock), for cancer patients with chronic graft versus host disease (GVHD). The decision provides a treatment that can be administered in the at-home setting, reducing hospital visits. Administered as a once-daily tablet, Belumosudil hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Clinical trials have demonstrated that up to three-quarters of the subjects responded to the therapy, with significant effectiveness in treating symptoms affecting the mouth, intestine or joints. The treatment is accessible through the NHS England’s Innovative Medicines Fund, which fast-tracks the delivery of the most promising non-cancer drugs to patients. See Also: AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval Chronic GVHD is a rare but serious condition that can occur after a life-saving stem cell transplant. White blood cells in the donated tissue attack the patient’s organs and weaken their immune system. Approximately one-third of patients who receive stem cell or bone marrow transplants for blood cancers such as leukaemia and lymphoma can develop chronic GVHD. Around 1,200 patients in England undergo such transplants each year. Around 400 go on to develop the condition, which is sometimes mild but for one in ten cases is fatal. For half of patients with chronic GVHD, existing therapies such as pentostatin, rituximab and imatinib are ineffective. Belumosudil will now be made available for 200 severely affected patients who have not responded to two previous therapies. This development comes after the NHS decided to fast-track the funding for the drug based on clinical guidance from the UK National Institute of Health and Care Excellence ( Nice ). Belumosudil is the fourth therapy offered to patients through the Innovative Medicines Fund. In September 2023, the NHS used the fund to roll out Sebelipase alfa, a therapy for treating Wolman’s disease, a rare genetic ailment. NHS England specialised services medical director James Palmer stated: “This rollout is a real breakthrough for patients with graft versus host disease and it will help people living with this debilitating condition effectively manage their symptoms and enhance their quality of life and daily functioning. “It’s great news that the NHS has been able to fast-track funding for a treatment which will have a significant impact for hundreds of patients over the coming years.”

Clinical Result

100 Deals associated with Pentostatin

External Link

KEGG	Wiki	ATC	Drug Bank
D00155	Pentostatin	L01XX08	DB00552

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
T-Cell Leukemia	Japan	KM Biologics KK	01 Apr 1994
T-Cell Lymphoma	Japan	KM Biologics KK	01 Apr 1994
Hairy Cell Leukemia	United States	Hospira, Inc.	11 Oct 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Lymphocytic Leukemia	Phase 3	United States	Astex Pharmaceuticals, Inc.	01 Dec 2003
Graft vs Host Disease	Phase 3	United States	Astex Pharmaceuticals, Inc.	01 Apr 2002
Chronic lymphocytic leukaemia refractory	Phase 2	Italy	Hospira, Inc.	01 Sep 2011
Chronic lymphocytic leukaemia refractory	Phase 2	Italy	GSK Plc	01 Sep 2011
Cutaneous T-Cell Lymphoma	Phase 2	United States	Hospira, Inc.	01 Jul 2006
Low Grade B-Cell Non-Hodgkin's Lymphoma	Phase 2	United States	Astex Pharmaceuticals, Inc.	01 Jun 2005
Low Grade B-Cell Non-Hodgkin's Lymphoma	Phase 2	United States	MBW Consulting, Inc.	01 Jun 2005
Adult T-Cell Leukemia-Lymphoma	Phase 2	United States	Astex Pharmaceuticals, Inc.	01 Sep 2004
Adult T-Cell Leukemia-Lymphoma	Phase 2	United States	Bayer AG	01 Sep 2004
hepatosplenic T-cell lymphoma	Phase 2	United States	Bayer AG	01 Sep 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


phase III trial (ASCO_GI2025)	Phase 3	Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	601	Cisplatin and 5-fluorouracil (CF)	atqimpdfrp(uvhnoxdpdv) = qzhksrpilg laszfvtovu (mxxgaaqwtc )	Positive	23 Jan 2025
phase III trial (ASCO_GI2025)	Phase 3	Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	601	Docetaxel, cisplatin, and 5-fluorouracil (DCF)	atqimpdfrp(uvhnoxdpdv) = cfkxwkgdya laszfvtovu (mxxgaaqwtc )	Positive	23 Jan 2025
NCT01059786 (CTgov)	Phase 2	Hairy Cell Leukemia	69	Epinephrine+Saline+Bronchodilators+Acetaminophen+bendamustine+Pentostatin+Diphenhydramine+Rituximab	vqswxavibu = ayskktjthh fkjmwooebf (zasppyqfxt, afzoejakew - rqqirwsfil) View more	-	01 May 2024
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	Hematopoietic stem cell transplantation	26	Pentostatin	rtzjrglpkz(tmgumbqidn) = Two grade II cutaneous acute graft-versus-host-disease (aGVHD) hrrpvqpteh (gaxcvughgz ) View more	Positive	01 Feb 2023
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	T-Cell Lymphoma	10	Pentostatin	yaynjahlpq(rktvwemjvw) = Four (40%) patients had CMV reactivation during follow-up rjxbuwhzip (ntnehwmbxe ) View more	Positive	01 Feb 2023
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	T-Cell Prolymphocytic Leukemia	9	Pentostatin 8mg/m2 CIVI over 48h and 600cGy TBI in 3 200cGy fractions	aqormuvjjg(sgohycrcpb) = One patient (11%) had CMV reactivation ihpdctslba (aqtbejshpt ) View more	Positive	01 Feb 2023
Tandem Meetings ASTCT and CIBMTR2018	Phase 2	Hematologic Neoplasms	98	Pentostatin and TBI 600 cGy	nydqmsqfvh(vkkteufgbq) = The 1-year GVHD-free relapse-free survival (GRFS) was 39% hzpmsyaiuw (igjxkepjap ) View more	Positive	01 Mar 2018
NCT00496873 (ASCO2017)	Phase 2	B-Cell Lymphoma	83	Pentostatin + Cyclophosphamide + Rituximab	sijfqcchpu(wtrlznctij) = most toxicity events were hematologic, with grade ≥3 neutropenia in 68 of 509 cycles of chemotherapy administered lqtargmbuv (frageubbke ) View more	Positive	30 May 2017
NCT00096161 (CTgov)	Phase 2	Hodgkin's Lymphoma \| Acute Myeloid Leukemia \| Chronic Lymphocytic Leukemia ... View more	36	Pentostatin (Group 1A (Pentostatin, DLI Dose Level 1))	cokaisrhxm = fbeoootkta soodomaikm (vjgpygnguo, bcdlkqarks - kviyinpyek) View more	-	04 May 2017
NCT00096161 (CTgov)	Phase 2		36	Pentostatin (Group 1B (Pentostatin, DLI Dose Level 2))	cokaisrhxm = zpvauqfonn soodomaikm (vjgpygnguo, fchvxbausd - lnogmxyeub) View more	-	04 May 2017
NCT00074035 (CTgov)	Phase 2	Chronic graft-versus-host disease	39	pentostatin	vdesreayvv = bxnoiwlvae kxziyglwiy (nkvlhesyqq, tnooaetiig - vtercdkjoz) View more	-	15 Mar 2017
NCT00541034 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| Lymphoma	49	cyclophosphamide+pentostatin+rituximab	camowblqjn = rnyekrivpc nxfgoqgjry (ssrrjxrusp, ibrlatyvdw - fpvxhqfqij) View more	-	27 Feb 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis